Javascript must be enabled to continue!
SPACs' Directors Network: Conflicts of Interest, Compensation, and Competition
View through CrossRef
We construct a director network for 972 SPACs that raised $271 billion from investors. First, we show that SPAC's investors receive lower returns and redeem more shares when directors sit on the board of another SPAC that IPOed later but found a target earlier. Second, we show that conflicted directors inefficiently allocate some targets to younger SPACs. Third, we study theoretically and empirically how new SPACs use compensation to compete for existing SPACs’ directors. Overall, decisions of SPACs' investors, directors, and sponsors raise serious corporate governance concerns and suggest that there is a need for stronger legal protection of investors.
Title: SPACs' Directors Network: Conflicts of Interest, Compensation, and Competition
Description:
We construct a director network for 972 SPACs that raised $271 billion from investors.
First, we show that SPAC's investors receive lower returns and redeem more shares when directors sit on the board of another SPAC that IPOed later but found a target earlier.
Second, we show that conflicted directors inefficiently allocate some targets to younger SPACs.
Third, we study theoretically and empirically how new SPACs use compensation to compete for existing SPACs’ directors.
Overall, decisions of SPACs' investors, directors, and sponsors raise serious corporate governance concerns and suggest that there is a need for stronger legal protection of investors.
Related Results
A Sober Look at SPACs
A Sober Look at SPACs
Special Purpose Acquisition Companies (SPACs)—touted as a better alternative to an IPO for taking a company public—have become the next big thing in the securities markets. This Ar...
A Sober Look at SPACs
A Sober Look at SPACs
Special Purpose Acquisition Companies (SPACs)—touted as a better alternative to an IPO for taking a company public—have become the next big thing in the securities markets. This Ar...
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
Essays in mergers and acquisitions
Essays in mergers and acquisitions
This dissertation studies mergers and acquisitions in which managerial compensation may give right to problems between principal and agent. In chapter 2, I focus on firms formed fo...
SPACs as an Asset Class
SPACs as an Asset Class
Special Purpose Acquisition Companies, or SPACs, have grown into one of the largest segments of the U.S. IPO market, raising more than $20 billion in gross proceeds since 2003. SP...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...
Verslaggeving door Europese Special Purpose Acquisition Companies (SPACs)
Verslaggeving door Europese Special Purpose Acquisition Companies (SPACs)
In 2021 hebben veel Special Purpose Acquisition Companies (‘SPACs’) een beursnotering verkregen. De verslaggeving van SPACs staat volop in de belangstelling, onder andere bij de IF...
Blank Check Acquisitions
Blank Check Acquisitions
Special Purpose Acquisition Companies (SPACs), a particular type of blank check firms, have risen dramatically since 2003 and account for one third of the U.S. IPO market in 2008. ...

